MAIA Biotechnology, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
MAIA NYSE American 2836 maiabiotech.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for MAIA Biotechnology, Inc.

MAIA Biotechnology Board Members Continue to Participate in Private Placement Financings - Dec 24th, 2025 6:01 am
MAIA Biotechnology Announces $1.51 Million Private Placement - Dec 16th, 2025 2:15 pm
MAIA’s Ateganosine Surges Ahead with Breakthrough Momentum as Pivotal Phase 3 Trial Initiates - Dec 11th, 2025 11:00 am
MAIA Biotechnology Announces First Patient Dosed in THIO-104 Phase 3 Pivotal Trial Evaluating Ateganosine as Third-Line Treatment for Advanced Non-Small Cell Lung Cancer - Dec 11th, 2025 7:00 am
MAIA Leadership Continues Insider Buying in 2025 and Trial Data Signals Breakout Potential - Dec 11th, 2025 6:00 am
MAIA Takes Aim at a $50B Immunotherapy Market with Breakthrough Telomere-Targeting Approach - Dec 10th, 2025 12:00 pm
MAIA Biotechnology Announces Open Market Purchases by CEO and Directors - Dec 1st, 2025 7:17 am
MAIA Biotechnology Highlights Ongoing Momentum of Ateganosine Clinical Program at SITC 2025 - Nov 21st, 2025 7:01 am
MAIA Biotechnology CEO Presents Telomere Targeting Efficacy at Romania’s 2025 Smart Diaspora Conference on Oncology Research and Innovation - Nov 20th, 2025 6:47 am
Diamond Equity Research Releases Update Note on MAIA Biotechnology, Inc. (NYSE: MAIA) - Nov 10th, 2025 6:00 am
MAIA Biotechnology Presents Trial in Progress Poster at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - Oct 27th, 2025 8:45 am
MAIA Biotechnology Details 30-Month Patient Survival in Ongoing Phase 2 Clinical Trial in Non-Small Cell Lung Cancer - Oct 23rd, 2025 6:36 am
MAIA Biotechnology Announces $736,600 Private Placement - Oct 13th, 2025 2:20 pm
Cancer drug maker takes sudden pivot into crypto - Oct 7th, 2025 1:13 pm
MAIA Biotechnology Announces $2.25 Million Private Placement - Sep 29th, 2025 2:30 pm
MAIA Biotechnology Awarded $2.3 Million Grant by National Institutes of Health for THIO-101 Phase 2 Trial of Cancer-Fighting Agent - Sep 24th, 2025 6:01 am
Maia’s NSCLC immunotherapy secures Phase II efficacy win - Sep 12th, 2025 6:33 am
MAIA Biotechnology Highlights Positive Efficacy Data from THIO-101 Phase 2 Clinical Trial in Non-Small Cell Lung Cancer - Sep 11th, 2025 7:27 am
MAIA Biotechnology Abstract Selected for Poster Presentation at 2025 IASLC World Conference on Lung Cancer - Sep 5th, 2025 7:03 am
MAIA Biotechnology Announces Publication of Interim Clinical Data on Telomere Targeting Anticancer Agent in Peer-Reviewed Journal Cells - Aug 27th, 2025 7:01 am